Statement: the primary trial reports the percentage of patients treated with Neratinib in Combination With Paclitaxel that suffer side effects that are serious enough to prevent an increase in dose or level of that treatment.
Primary_evidence: Outcome Measurement:    Dose Limiting Toxicity Incidence of Neratinib in Combination With Paclitaxel   Dose Limiting Toxicity in subjects with solid tumors treated with neratinib, administered daily, in combination with paclitaxel 80 mg/m² IV on days 1, 8, and 15 of a 28 day cycle.   Time frame: From first dose date through day 28 Results 1:    Arm/Group Title: Neratinib 160 mg + Paclitaxel 80 mg/m    Arm/Group Description: Neratinib 160 mg qd + Paclitaxel 80 mg/m  IV on days 1, 8, and 15 of a 28 day cycle.   Overall Number of Participants Analyzed: 3   Measure Type: Count of Participants   Unit of Measure: Participants  0   0.0% Results 2:    Arm/Group Title: Neratinib 240 mg + Paclitaxel 80 mg/m    Arm/Group Description: Neratinib 240 mg qd + Paclitaxel 80 mg/m  IV on days 1, 8, and 15 of a 28 day cycle.   Overall Number of Participants Analyzed: 5   Measure Type: Count of Participants   Unit of Measure: Participants  0   0.0%